Wall Street has already declared a winner in the race to develop new treatments for hepatitis C, a virus that infects 3.2 million Americans that is the leading cause of liver transplantation in the United States. It’s Gilead Sciences GILD -4.07%. Everyone knows that Gilead’s Sovaldi, already the best drug launch ever with $2.3 billion in sales in its first quarter, is set to dominate this new market.
Hey, check out all the research scientist jobs. Post your resume today!
